Floatz logo

Perflutren Lipid Microsphere Intravenous Suspension

Anatomic Stage III Breast Cancer AJCC v8

UNC Lineberger Comprehensive Cancer CenterPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

890 Active assets in the Anatomic Stage III Breast Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Perflutren Lipid Microsphere Intravenous Suspension is also rated in:

breast carcinomaDormant
B
Indicative ·
62 / 100
View asset →
kidney cancerDormant
B
Indicative ·
58 / 100
View asset →
prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →